The 66 linked references in paper R. Samsonov B., Z. Radzhabova A., Yu. Cheburkin V., V. Klyuge A., E. Tkachenko V., A. Malek V., Р. Самсонов Б., З. Раджабова А., Ю. Чебуркин В., В. Клюге А., Е. Ткаченко В., А. Малек В. (2017) “ЭПИГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ РЕГУЛЯЦИИ ГЕННОЙ ЭКСПРЕССИИ В РАЗВИТИИ ПЛОСКОКЛЕТОЧНОГО РАКА ГОЛОВЫ И ШЕИ: ТЕРАПЕВТИЧЕСКИЕ ПЕРСПЕКТИВЫ // EPIGENETIC REGULATION OF GENE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: THERAPEUTIC PERSPECTIVES” / spz:neicon:ogsh:y:2016:i:4:p:35-44

  1. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59. DOI: 10.1056/NEJMra072067.
  2. Bakhtiar S.M., Ali A., Barh D. Epigenetics in head and neck cancer. Methods Mol Biol 2015;1238:751–69. DOI: 10.1007/978-1-4939-1804-1_39.
  3. Demokan S., Dalay N. Role of DNA methylation in head and neck cancer. Clin Epigenetics 2011;2(2):123–50. DOI: 10.1007/s13148-011-0045-3.
  4. Shridhar K., Walia G.K., Aggarwal A. et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncol 2016;53:1–9. DOI: 10.1016/j.oraloncology.2015.11.012.
  5. Chen Y.W., Kao S.Y., Wang H.J., Yang M.H. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer 2013;119(24):4259-67. DOI: 10.1002/cncr.28356.
  6. URL: http://www.mirbase.org/.
  7. Gunaratne P.H., Creighton C.J., Watson M., Tennakoon J.B. Large-scale integration of microRNA and gene expression data for identification of enriched microRNAmRNA associations in biological systems. Methods Mol Biol 2010;667:297–315. DOI: 10.1007/978-1-60761-811-9_20.
  8. Gulyaeva L.F., Kushlinskiy N.E. Regulatory mechanisms of microRNA expression. J Transl Med 2016;14(1):143. DOI: 10.1186/s12967-016-0893-x.
  9. Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287–314. DOI: 10.1146/annurev-pathol-012513-104715.
  10. Courthod G., Franco P., Palermo L. et al. The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 2014;19(5):5704–16. DOI: 10.3390/molecules19055704.
  11. John K., Wu J., Lee B.W., Farah C.S. MicroRNAs in Head and Neck Cancer. Int J Dent 2013;2013:650218. DOI: 10.1155/2013/650218.
  12. Choi J.D., Lee J.S. Interplay between Epigenetics and Genetics in Cancer. Genomics Inform 2013;11(4):164–73. DOI: 10.5808/GI.2013.11.4.164.
  13. Baylin S.B., Jones P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. DOI: 10.1101/cshperspect.a019505.
  14. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10(5):295–304. DOI: 10.1038/nrg2540.
  15. Sato F., Tsuchiya S. Meltzer S.J., Shimizu K. MicroRNAs and epigenetics. FEBS J 2011;278(10):1598–609. DOI: 10.1111/j.1742-4658.2011.08089.x.
  16. Wu L., Mao L., Qi Y. Roles of dicer-like and argonaute proteins in TAS-derived small interfering RNA-triggered DNA methylation. Plant Physiol 2012;160(2):990–9. DOI: 10.1104/pp.112.200279.
  17. Wu L., Zhou H., Zhang Q. et al. DNA methylation mediated by a microRNA pathway. Mol Cell 2010;38(3):465–75. DOI: 10.1016/j.molcel.2010.03.008.
  18. Wong T.S., Gao W., Chan J.Y. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay. Biomed Res Int 2014;2014:126038. DOI: 10.1155/2014/126038.
  19. Entrevan M., Schuettengruber B., Cavalli G. Regulation of Genome Architecture and Function by Polycomb Proteins. Trends Cell Biol 2016;26(7):511–25. DOI: 10.1016/j.tcb.2016.04.009.
  20. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10(10):697–708. DOI: 10.1038/nrm2763.
  21. Li X., Lin Y., Yang X. et al. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2016;473(4):913–9. DOI: 10.1016/j.bbrc.2016.03.150.
  22. Sander S., Bullinger L., Klapproth K. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112(10):4202–12. DOI: 10.1182/blood-2008-03-147645.
  23. Varambally S., Cao Q., Mani R.S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322(5908):1695–9. DOI: 10.1126/science.1165395.
  24. Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30(3):372–8. DOI: 10.1002/stem.1035.
  25. Lundberg M., Renkonen S., Haglund C. et al. Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas. Acta Otolaryngol 2016;136(5):501–5. DOI: 10.3109/00016489.2015.1122227.
  26. Hauser B., Zhao Y., Pang X. et al. Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One 2015;10(3):e0116321. DOI: 10.1371/journal.pone.0116321.
  27. Yu X., Jiang X., Li H. et al. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev 2014;23(6):576–85. DOI: 10.1089/scd.2013.0308.
  28. Swierczynski S., Klieser E., Illig R. et al. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015;15(5):651–64. DOI: 10.1517/14712598.2015.1025047.
  29. Le J.M., Squarize C.H., Castilho R.M. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells 2014;6(5):511–25. DOI: 10.4252/wjsc.v6.i5.511.
  30. Cho J.H., Dimri M., Dimri G.P. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015;290(16):10555–67. DOI: 10.1074/jbc.M114.624361.
  31. Koumangoye R.B., Andl T., Taubenslag K.J. et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer 2015;14:24. DOI: 10.1186/s12943-014-0284-y.
  32. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J Clin 2010;60(6):376–92. DOI: 10.3322/caac.20085.
  33. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010;19(5):698–711. DOI: 10.1016/j.devcel.2010.10.005.
  34. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009;41(1):87–95. DOI: 10.1016/j.biocel.2008.09.005.
  35. Roman-Gomez J., Agirre X., JiménezVelasco A. et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009;27(8):1316–22. DOI: 10.1200/JCO.2008.19.3441.
  36. Bandres E., Agirre X., Bitarte N. et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009;125(11):2737–43. DOI: 10.1002/ijc.24638.
  37. Lujambio A., Calin G.A., Villanueva A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105(36):13556–61. DOI: 10.1073/pnas.0803055105.
  38. Zhu D.D., Zhang J., Deng W. et al. Significance of NF-kappaB activation in immortalization of nasopharyngeal epithelial cells. Int J Cancer 2016;138(5):1175–85. DOI: 10.1002/ijc.29850.
  39. Toyota M., Suzuki H., Sasaki Y. et al. Epigenetic silencing of microRNA-34b/c and Bcell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68(11):4123–32. DOI: 10.1158/0008-5472.CAN-08-0325.
  40. Jia L.F., Wei S.B., Mitchelson K. et al. miR-34a inhibits migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14. PLoS One 2014;9(9):e108435. DOI: 10.1371/journal.pone.0108435.
  41. Cheng Y., Li Y., Nian Y. et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 2015;15:306. DOI: 10.1186/s12885-015-1303-0.
  42. Peng X.H., Huang H.R., Lu J. et al. MiR124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer 2014;13:186. DOI: 10.1186/1476-4598-13-186.
  43. Shin K.H., Pucar A., Kim R.H. et al. Identification of senescence-inducing microRNAs in normal human keratinocytes. Int J Oncol 2011;39(5):1205–11. DOI: 10.3892/ijo.2011.1111.
  44. Ando T., Yoshida T., Enomoto S. et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009;124(10):2367–74. DOI: 10.1002/ijc.24219.
  45. Dang J., Bian Y.Q., Sun J.Y. et al. Micro RNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2013;42(4):315–21. DOI: 10.1111/jop.12012.
  46. Kozaki K., Imoto I., Mogi S. et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68(7):2094-105. DOI: 10.1158/0008-5472.CAN-07-5194.
  47. Wiklund E.D., Bramsen J.B., Hulf T. et al. Coordinated epigenetic repression of the miR200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128(6):1327–34. DOI: 10.1002/ijc.25461.
  48. Tamagawa S., Beder L.B., Hotomi M. et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 2014;33(4):879–86. DOI: 10.3892/ijmm.2014.1625.
  49. Bueno M.J.1, Pérez de Castro I., Gómez de Cedrón M. et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL oncogene expression. Cancer Cell 2008;13(6):496–506. DOI: 10.1016/j.ccr.2008.04.018.
  50. Furuta M., Kozaki K.I., Tanaka S. et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31(5):766–76. DOI: 10.1093/carcin/bgp250.
  51. Erlich R.B., Rickwood D., Coman W.B. et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009;63(3):381–9. DOI: 10.1007/s00280-008-0747-1.
  52. Witt D., Burfeind P., von Hardenberg S. et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 2013;34(5):1115–24. DOI: 10.1093/carcin/bgt019.
  53. Gan C.P., Hamid S., Hor S.Y. et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012;34(3):344–53. DOI: 10.1002/hed.21734.
  54. Lee S.H., Nam H.J., Kang H.J. et al. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. Oncol Rep 2015;34(4):2065–71. DOI: 10.3892/or.2015.4145.
  55. Oikawa H., Goh W.W., Lim V.K. et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int 2015;91:62–71. DOI: 10.1016/j.neuint.2015.10.010.
  56. Trécul A., Morceau F., Gaigneaux A. et al. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol 2014;92(2):299–311. DOI: 10.1016/j.bcp.2014.07.035.
  57. Datta J., Islam M., Dutta S. et al. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 2016;56:32–9. DOI: 10.1016/j.oraloncology.2016.02.015.
  58. Datta J., Smith A., Lang J.C. et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cɛ. Oncogene 2012;31(36):4045–53. DOI: 10.1038/onc.2011.565.
  59. Piao L., Zhang M., Datta J. et al. Lipidbased nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20(6):1261–9. DOI: 10.1038/mt.2012.67.
  60. Jiang L., Liu X., Kolokythas A. et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010;127(3):505–12. DOI: 10.1002/ijc.25320.
  61. Liu X., Wang C., Chen Z. et al. Micro RNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011;440(1):23–31. DOI: 10.1042/BJ20111006.
  62. Alhazzazi T.Y., Kamarajan P., Joo N. et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117(8):1670–8. DOI: 10.1002/cncr.25676.
  63. Cheng Y., Mai J., Hou T., Ping J. Micro RNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3. Biochem Biophys Res Commun 2016;474(1):57–63. DOI: 10.1016/j.bbrc.2016.04.065.
  64. Humphreys K.J., Cobiac L., Le Leu R.K. et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013;52(6):459–74. DOI: 10.1002/mc.21879.
  65. Hu S., Liu L., Chang E.B. et al. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol Cancer 2015;14:180. DOI: 10.1186/s12943-015-0450-x.
  66. Chen H.C., Chen G.H., Chen Y.H. et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009;100(6):1002–11. DOI: 10.1038/sj.bjc.6604948.